Menu

The public needs to know

0 Comment

Its management is also costly and leaves most families poor besides the fact that available management strategies only slows down the disease’s effects. I, in this paper, present a proposal for a business of developing a new drug for cancer patients in order to reduce cancer’s currently experienced effects. Economic situation The new drug development is expected to cost about one billion U.S. dollars, inclusive of involved tax and miscellaneous expenses. Most of the projected cost will be invested in research and will be used to purchase research facilities and to offer remunerations and incentives to researchers, research assistants, and research participants. Some donors, research agencies, government institutions, and nongovernmental organizations have pledged their support for the initiative, and received and pledged donations amount to $ 400 million. This is, however, 60 percent short of the total required amount. As a result, the next phase of the drug development project that was scheduled to kick off in four months time may be delayed. Being a social initiative, the drug development program is not profit oriented and will rely on donations from well-wishers. We therefore appeal for further donations from people and organizations to facilitate the project that will develop a low cost drug for managing cancer (Neidle, 2011). Special needs of the target population The project seeks to meet diversified social needs. The overall benefit of the drug in suppressing cancerous growths and involved consequences on patients and the society will serve these needs. One of the special needs is the preservation of cancer victims’ lives. Even though the developed drug does not offer treatment to the disease, preliminary research indicates that it will greatly suppress cancerous growths, at any stage, and therefore sustain victims’ lives. The suppressed growth will further minimize and possibly mitigate pain among cancer patients to achieve high quality of life. Retention of a cancer patient’s cognitive ability is another special need that the developed drug will meet. This will be derived from the drug’s potential to suppress further growth and to subsequently control realized symptoms among patients. Preliminary tests have also indicated the drug’s milder side effects, as compared to those of the currently applied cancer management techniques such as chemotherapy, which will meet the need for more effective drugs with less significant side effects (Livestrong, n.d.). Process The proposed drug development project will follow the laid down guidelines for developing and testing a new drug. The first involved step, preclinical research, has been done. This involved scientific research into development of cancerous cells, involved factors into such growth and proposed drug components for countering the growths. The next stage of the development process will involve a multi staged set of trials with increasing number of test participants at each advanced stage. Each of the trial stages will involve evaluation of effects of the drug on cancerous growth and possible effects on the volunteers. The process will involve three trials in which 50 volunteers will participate in the first trial, 200 participants will be involved in the second trial and 2000 in the third trial. The drug, upon successful tests, will then be filed with the responsible national drug agency for approval. The remaining stages of the